DNA Trading Analysis - 10/05/2026 01:08 PM — TRU-SENTIMENT

News Headlines & Context:

The following items are based on general knowledge and are provided for contextual background only, separate from the data-driven analysis below.

• Ginkgo Bioworks (DNA) announced a new cell-engineering partnership with a major pharmaceutical client, potentially boosting long-term revenue visibility.
• Company disclosed a narrowed quarterly net loss versus prior year, though still unprofitable with negative EPS.
• Biotech sector ETF inflows increased amid broader risk-on sentiment in early October 2026.
• Management highlighted cash-runway extension via recent convertible note offering, reducing near-term dilution fears.
• No confirmed imminent earnings date in public records; fiscal year end was December 2025 per fundamentals.

Context: These headlines reflect speculative biotech interest and partnership catalysts that may partially explain the strong September–October price surge seen in the embedded daily data, but they are not a substitute for the quantitative signals below.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data for DNA:

• Trailing EPS is -5.00; company is unprofitable with no positive earnings trend available.
• Trailing PE, forward PE, PEG ratio, price-to-book, profit margins, ROE, debt-to-equity, and free cash flow are all null or unavailable.
• Revenue growth, total revenue, and analyst target mean price are null; no analyst consensus or recommendation key provided.
• Market cap is $959,453,586.00 with shares outstanding of 67,340,000.00.
• Institutional ownership is 27.61%, indicating limited institutional sponsorship.
• Beta is 2.32 and historical volatility is 102.29%, showing extreme systematic and realized risk.
• 52-week range: $5.37 low to $17.58 high; current price near middle-upper band historically.
• Dividend yield 0.00%; no dividend.

Fundamental concerns dominate: negative earnings, missing margin/value metrics, and high volatility contrast with the strong technical uptrend in the embedded price data. Fundamentals do not support the rally; technicals are decoupled from underlying profitability.

Current Market Position:

From embedded data: Daily close on 2026-10-02 was $12.36. Minute bars show 2026-10-02 open $13.00, low $12.86 early, and 2026-10-05 midday last bar at $14.25 after highs near $14.80. Recent price action shows a sharp run-up from August $6.52 low to October $14.80 area.

Intraday momentum on 10-05 turned down from $14.80 to $14.25 on rising volume (201,862), signaling short-term profit-taking within an uptrend.

Technical Analysis:

SMA alignment is bullish: price > SMA 5 > SMA 20 > SMA 50, with no bearish crossovers. RSI at 82.21 is overbought, implying exhaustion risk. MACD histogram positive (0.26) confirms bullish momentum. Price is above Bollinger upper ($13.17) on daily close basis only if using 10-05 tape; embedded daily close was $12.36 (below upper). Bands are expanding. Price sits in top 84% of 30-day range ($6.52–$13.41).

True Sentiment Analysis (Delta 40-60 Options):

From embedded True Sentiment options data (2026-10-05):

Call Volume: $726,395.00 (42.2%) Put Volume: $993,300.00 (57.8%) Total: $1,719,695.00

Sentiment is Balanced per methodology (Delta 40-60 only). Put dollar volume exceeds calls by $266,905.00, showing slight defensive conviction. Call trades (16) outnumber put trades (5) but smaller notional per trade. Pure directional positioning suggests no overwhelming near-term bias despite vertical price ascent. Divergence: technicals are strongly bullish while options flow is balanced/put-leaning.

Key Price Levels (observational only):